Meet PSI at Chinese Society of Nuclear Medicine (CSNM) 2026!
PSI CRO is attending CSNM 2026 to discuss how sponsors can operationalize increasingly complex radiopharmaceutical development programs while maintaining predictable delivery across global sites.
Radiopharmaceutical development is moving beyond early innovation into operational scale-up. Sponsors now face increasing pressure around isotope supply coordination, imaging workflows, site readiness, and combination therapy execution. PSI has supported 40% of all industry pivotal radiopharmaceutical and radioligand therapy trials, with specialized operational infrastructure designed specifically for targeted radionuclide therapy programs.
At CSNM 2026, the PSI team will discuss practical approaches to site activation, imaging operations, patient pathway management, and AI-enabled site intelligence for radiopharmaceutical studies across oncology and emerging non-oncology indications.
Visit PSI at our booth
Meet with the PSI team to discuss radiopharmaceutical trial delivery strategies and explore how SYNETIC™ and INTELIA™ support site identification, feasibility, and operational execution for complex global studies.
Attending team members:
Related resources:
Blog: Radiopharmaceutical advances expose the need for specialized trial support
Case Study: The road to a phase 3 radiopharmaceutical trial in China
Webinar: From Early Promise to Pivotal Success: Operationalizing RLT Trials for Scale [Orano Med + PSI]
White Paper: The operational reality of agentic AI in phase 2-3 trials
